Event > Conference >

TARGET TO PATIENT 2026 – T2P26

Join Dr. Kostrzewski (CN Bio) and other industry, academia and government experts to challenge the existing approaches to target selection and translation and learn about the next era of drug discovery.

T2P26 Event Thumbnail | target to patient 2026

20-21 April 2026

Cambridge, UK

More Info

Join Dr. Tomasz Kostrzewski (CSO), from CN Bio, for his talk at the The Society for Medicines Research (SMR) meeting – TARGET TO PATIENT 2026, 20-21 April, 2026.

Attend our presentation

Title: Accelerating the adoption of microphysiological systems in drug development through collaboration and validation

Session: Complex in vitro models (Session 4)

Date: 21 April, 2026, Tuesday

Time: 10:55 (BST)

Duration: 25 minutes

Presenter: Dr Tomasz Kostrzewski

This bi-annual meeting brings together individuals from industry, academia and government, interested in challenging the existing approaches to target selection and translation to usher in the next era of drug discovery. The sessions will focus on ground-breaking advances in

Machine Learning and Target identification
Rewiring biology through induced proximity
Impact of advances in analytical sciences
Complex in vitro models
Improving clinical trial outcomes

About the Presenter:

Dr. Tomasz Kostrzewski

CSO

Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was promoted to VP of Science and Technology and then to Chief Scientific Officer in 2023, with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.

Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.